Somatrogon (Ngenla)

Somatrogon is the third once-weekly growth hormone on this site, after lonapegsomatropin and somapacitan — a third genuinely different chemistry trick again, fusing hGH to a heavily sugared peptide tail instead of using a prodrug or an albumin-binder. It's also the odd one out in a specific way: approved in Canada, the EU, Japan, Australia and South Korea well before the FDA finally cleared it in 2023, and still pediatric-only everywhere, after its own dedicated adult trial missed its primary endpoint.

A third once-weekly hGH, a third different trick

Somatrogon (Ngenla, Pfizer/OPKO Health) is this site's third once-weekly recombinant human growth hormone, after lonapegsomatropin (a slow-release prodrug) and somapacitan (reversible albumin binding) — and it solves the same half-life problem with a third, genuinely different piece of chemistry. Somatrogon fuses the growth hormone molecule to three copies of the carboxy-terminal peptide (CTP) from human chorionic gonadotropin's beta subunit, a heavily O-glycosylated tail borrowed from an entirely different hormone. Those sugar chains slow the fused protein's clearance from the body, stretching an otherwise short-acting hormone into a once-weekly injection — the same clinical goal as the other two products, reached by a third distinct route.

The pediatric Phase 3 trial

Somatrogon's pediatric approval rests on a global Phase 3 trial (Deal CL, Steelman J, Vlachopapadopoulou E, et al., "Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study," J Clin Endocrinol Metab 2022;107(7):e2717-e2728, PMID 35405011, DOI 10.1210/clinem/dgac220) that randomized 228 treatment-naive, prepubertal children with growth hormone deficiency 1:1 to once-weekly somatrogon or daily somatropin (Genotropin), with 224 receiving at least one dose over 12 months. Annualized height velocity at month 12 was 10.10 cm/year with somatrogon versus 9.78 cm/year with daily somatropin — a 0.33 cm/year difference favoring somatrogon (95% CI -0.24 to 0.89), comfortably within the trial's prespecified noninferiority margin (-1.8 cm/year). Adverse-event rates were similar between arms (78.9% somatrogon vs 79.1% somatropin, mostly mild-to-moderate), and the trial met its noninferiority objective.

Approved everywhere else first, then a US rejection

Somatrogon's regulatory path ran through several other countries before it reached the US: Health Canada approved it first, in October 2021, followed by the European Commission in February 2022 and later authorizations in Japan, Australia and South Korea. The FDA, reviewing largely the same pediatric data, instead issued a Complete Response Letter on 21 January 2022 — Pfizer and OPKO disclosed the rejection publicly but neither company nor the FDA detailed the specific deficiency in their public statements. Pfizer resubmitted, and the FDA approved Ngenla on 27 June 2023 for pediatric patients 3 years and older — roughly a year and a half after the drug had already reached patients in Canada, Europe and Japan.

Why it's still pediatric-only

Unlike lonapegsomatropin and somapacitan, both of which added adult growth hormone deficiency indications after their pediatric approvals, somatrogon has no adult indication anywhere. Pfizer did run a Phase 3 adult trial — 202 adults randomized 2:1 to somatrogon or placebo over a 26-week double-blind period — but its primary endpoint, change in trunk fat mass from baseline to week 26, did not reach statistical significance (-0.37 kg with somatrogon versus +0.03 kg with placebo, p=0.0821), even though several secondary measures (including lean body mass and trunk fat as a percentage of total body fat) did favor somatrogon (published in Pituitary, 25 March 2026, DOI 10.1007/s11102-026-01661-1). Pfizer had filed for an adult indication in the EU on the strength of that trial, then withdrew the application on 20 December 2024 rather than pursue it against a missed primary endpoint. No adult application appears to have reached the FDA at all.

Current status

Ngenla is actively marketed by Pfizer as a once-weekly prefilled pen (dosed at 0.66 mg/kg/week) for pediatric growth hormone deficiency in the US, Canada, the EU, Japan, Australia and South Korea. As with any approved hGH product, its trial evidence is specific to diagnosed pediatric growth hormone deficiency — see this site's Human Growth Hormone page for why that doesn't extend to off-label anti-aging or bodybuilding use in someone who isn't GH-deficient. There is no wellness or grey-market interest in somatrogon specifically that we could find — it's a prescription-only pediatric endocrinology product, not something sold outside that channel.